405 related articles for article (PubMed ID: 17363599)
1. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
2. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
3. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
[TBL] [Abstract][Full Text] [Related]
5. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
6. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
Tolmachev V; Nilsson FY; Widström C; Andersson K; Rosik D; Gedda L; Wennborg A; Orlova A
J Nucl Med; 2006 May; 47(5):846-53. PubMed ID: 16644755
[TBL] [Abstract][Full Text] [Related]
7. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
[TBL] [Abstract][Full Text] [Related]
8. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
Orlova A; Tolmachev V; Pehrson R; Lindborg M; Tran T; Sandström M; Nilsson FY; Wennborg A; Abrahmsén L; Feldwisch J
Cancer Res; 2007 Mar; 67(5):2178-86. PubMed ID: 17332348
[TBL] [Abstract][Full Text] [Related]
9. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
Tran T; Orlova A; Sivaev I; Sandström M; Tolmachev V
Int J Mol Med; 2007 Mar; 19(3):485-93. PubMed ID: 17273798
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
12. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
13. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
Fortin MA; Orlova A; Malmström PU; Tolmachev V
Int J Mol Med; 2007 Feb; 19(2):285-91. PubMed ID: 17203203
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.
Shi J; Liu Z; Jia B; Yu Z; Zhao H; Wang F
Amino Acids; 2010 Jun; 39(1):111-20. PubMed ID: 19941017
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
19. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
